Clinical CRO ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer GmbH is adapting a process of integrating medical review procedures into Pharmacovigilance risk management, a method that will lead to better Pharmacovigilance practices.
(firmenpresse) - ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives from the pharmaceutical and biotech industries with innovative solution providers. At the event, Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer, presented her findings and experiences in striking a balanced medical review process to build a robust Pharmacovigilance strategy.
‘The talk generated a tremendous amount of interest in the topic and resulted in positive feedback and interesting discussions with delegates’ says Dr Treichel. ‘We were particularly pleased about specific requests that were made by trial sponsors at the event. Our Pharmacovigilance and Medical Review teams are very happy to provide this special service and therefore meet the growing demand of pharmaceutical and biotech companies.’
Most Pharmacovigilance systems suffer either from a complete lack of medical review integration or, at the other extreme, a single all-inclusive process resulting in over-integration. By adapting a balanced medical review process ICRC-Weyer is able to build a robust Pharmacovigilance strategy.
Dr Treichel’s talk featured several aspects of this topic, including the assessment of current risk management approaches to pinpoint drawbacks and improve Pharmacovigilance strategies, the identification of expected benefits, potential difficulties and practical considerations of medical review for effective integration, examining past case studies to uncover unforeseen threats and debunk false risks as well as improving processes and minimising overall risks through the successful execution of integrated medical review.
The presentation can be accessed via ICRC-Weyer’s website.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.
ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.
Dr. Ulrike Treichel
ICRC-Weyer GmbH
Boelschestrasse 2, 12587 Berlin, Germany
Phone: +49 30 403937-0
E-mail: Ulrike.Treichel(at)icrc-weyer.com
ICRC-Weyer GmbH
Boelschestrasse 2, 12587 Berlin, Germany
Phone: +49 30 403937-0
E-mail: martin.krainz(at)icrc-weyer.com
Datum: 08.01.2013 - 17:10 Uhr
Sprache: Deutsch
News-ID 217626
Anzahl Zeichen: 2421
contact information:
Kategorie:
Trials
Typ of Press Release: Produktankündigung
type of sending: Veröffentlichung
Date of sending: 08.01.2013
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clinical CRO ICRC-Weyer To Enhance Pharmacovigilance Risk Management"
steht unter der journalistisch-redaktionellen Verantwortung von
ICRC-Weyer GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
